Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04559152
Other study ID # 9/UN5.2.3.1/PPM/KP-DRPM/2019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2019
Est. completion date December 30, 2019

Study information

Verified date September 2020
Source Universitas Sumatera Utara
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This experimental study was conducted with pre-test/post-test control groups and double-blind randomization from March to December 2019 at Universitas Sumatera Utara Hospital and others in Medan. Subjects were pregnant mothers in second or third trimester and with their newborns who met the inclusion criteria. Subjects were divided into two groups and administered either zinc supplementation 20 mg/day or placebo, respectively, for 12 weeks. The parameters assessed were maternal serum zinc levels cord blood osteocalcin and birth length measurements.


Description:

Patients and Study Design This was an experimental study with pre-test/post-test control groups, double-blind with randomization block technique. This study was conducted from March to December 2019 in the obstetrics and neonatology unit of Universitas Sumatera Utara Hospital, Malahayati Islamic Hospital and Royal Maternity Hospital in Medan. Research subjects were pregnant mothers with their newborns who met the inclusion criteria. The study samples were divided into two groups and administered either zinc supplementation 20 mg/day or placebos, respectively, for 12 weeks. The zinc tablets or placebos were given in the morning after meals. All subjects were also given iron and folic acid tablets in accordance with the Indonesian government program. Subjects were healthy pregnant mothers in their second or third trimester, 20-35 years old, with a height of >150 cm and no indication of cons following this study, as determined by obstetrician and gynaecology specialists; subjects were enrolled with a consecutive sampling technique. Births involving twins, congenital abnormalities, prematurity (gestation age <37 weeks) or stillbirth were excluded.

Informed consent was given by all subjects' legal guardians following the provision of sufficient information prior to the study.

This study was approved by the Health Research Ethical Committee, School of Medicine, Universitas Sumatera Utara in accordance with the principles of the Helsinki Declaration (No.179/TGL/FK USU-RSUP HAM/2019).

Methods The parameters assessed in this study were maternal serum zinc levels, cord blood osteocalcin and birth length measurements. Maternal serum zinc levels were measured twice with 6 ml of vein blood each time, both during initial antenatal care and after 12 weeks of supplementation. Samples were subsequently centrifuged for 15 minutes at 3000 rpm. Specimens were processed by the inductively coupled plasma-mass spectrometry (ICP-MS) method using Agilent 7700 analyser (Santa Clara, USA, 2014). Normal serum zinc levels were defined based on a cut-off value of ≥ 56 µg/dL in accordance with Second National Health and Nutrition Examination Survey data from 1976-1980 (NHANES II).

Cord blood osteocalcin levels were measured with 6 ml cord blood samples prior to delivery, which were subsequently centrifuged for 15 minutes at 1000 rpm using Cobas e601 analyser (Roche Diagnostic, Mannheim, Germany) and N-Mid Osteocalcin (Abbexa) reagent. Osteocalcin was measured using the enzyme-linked immuno-sorbent assay (ELISA) method, and in accordance with Prodia clinical laboratory standards.

Neonatal birth length was performed with a SECA 232 digital baby scale for length with an accuracy of 0.1 cm. Maternal zinc intake was calculated in accordance with the NutriSurvey 2007 Indonesian version.

Statistical Analysis Descriptive analyses, correlation tests, and linear regression tests were performed using SPSS version 23.0 (SPSS Inc., Chicago, Illinois, USA). Statistical significance was considered at a p-value < 0.05 with a 95% confidence interval.


Recruitment information / eligibility

Status Completed
Enrollment 71
Est. completion date December 30, 2019
Est. primary completion date December 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria:

- Healthy pregnant mothers in their second or third trimester

- Age 20-35 years old

- Minimal height 150 cm

Exclusion Criteria:

Pregnant mothers in high-risk conditions such as

- severe malnutrition

- eclampsia

- gestational diabetes

- liver diseases

- kidney diseases

Neonatal with

- twin babies

- congenital anomalies

- prematurity (gestation age <37 weeks)

- stillbirth

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Zinc Supplementation Group
Enrolled subjects received zinc capsule 20mg daily in the morning after meal for 12 weeks
Placebo Group
Enrolled subjects received placebo tablet, which was inserted into capsule of the same shape and color as zinc capsule, daily in the morning after meal for 12 weeks

Locations

Country Name City State
Indonesia Universitas Sumatera Utara Medan Sumatera Utara

Sponsors (1)

Lead Sponsor Collaborator
Universitas Sumatera Utara

Country where clinical trial is conducted

Indonesia, 

References & Publications (1)

Rohmawati L, Keumala DS, Sitepu M. Maternal Zinc Intake and Its Correlation with Maternal Serum Zinc Levels and Neonatal Birth Weight/Length. Pak. J. Nutr., 19 (5): 245-252, 2020. DOI: 10.3923/pjn.2020.245.252

Outcome

Type Measure Description Time frame Safety issue
Primary Zinc Supplementation During Pregnancy Prevent Stunting Occurence to the Newborn: Analysis of Maternal Serum Zinc, Cord Blood Osteocalcin and Neonatal Birth Length Maternal serum zinc level (after intervention) was measured and analysed statistically for its correlation with mean cord blood osteocalcin levels and median neonatal birth lengths 12 weeks up to childbirth
Secondary Correlation Between Maternal Zinc Supplementation with Maternal Serum Zinc Levels Maternal Serum Zinc level was measured before and after intervention. Participants dietary intake also will be accounted and calculated via food recall.
The serum zinc level before and after intervention will then be analysed statistically to check for any correlation between zinc dietary intake and serum zinc level
12 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03353662 - Sub Regional Micronutrient Survey in Ethiopia
Completed NCT02126293 - Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant Phase 3
Terminated NCT01472211 - Water-based Zinc Intervention Trial in Zinc Deficient Children Phase 0
Completed NCT01061307 - An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand Phase 0
Recruiting NCT03421314 - Effect of Zinc and Selenium Supplementation on HIV+ Individuals on Antiretroviral Treatment. N/A
Completed NCT02292303 - Clinical Trial to Determine the Bioavailability of Three Different Zinc Preparations N/A
Completed NCT02241330 - Efficacy of Zn Biofortified Wheat in Improving Zn Status in Indian School Children With Low Zn Status N/A
Completed NCT01221129 - Zinc and the Synthesis of Zinc Binding Proteins (Protocol B) N/A
Completed NCT04632771 - Nutritional Status and Bouillon Use in Northern Ghana
Recruiting NCT05236374 - Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc N/A
Completed NCT02758444 - Effects of EED on Zn Absorption and Retention in Children From a MNP N/A
Completed NCT02760095 - Effects of EED on Zn Absorption and Retention in Children From a Standard Dose
Completed NCT02233764 - Effect of Iron/Zinc-Biofortified Pearl Millet on Growth and Immunity in Children Aged 12-18 Months in India N/A
Recruiting NCT05527899 - Zinc Intervention in Elderly for Prevention of Pneumonia Phase 2/Phase 3
Terminated NCT04983667 - Zinc-AA Supplementation During Pregnancy & Lactation to Assess Effects on ASD Prevalence in Offspring N/A
Completed NCT03293641 - Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya N/A
Completed NCT05778383 - Zinc Supplementation Impact in Acute COVID-19 Clinical Outcomes Phase 4
Completed NCT01062347 - A Novel Bio-marker of Zinc Status Phase 1
Recruiting NCT05085834 - Zinc Effect on Inflammation and Cardiovascular Risk in HIV Early Phase 1
Completed NCT02321865 - Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency Phase 3